Medivolve Inc. (MEDV.NE)
| Previous Close | 0.0300 |
| Open | 0.0250 |
| Bid | 0.0200 x N/A |
| Ask | 0.0250 x N/A |
| Day's Range | 0.0200 - 0.0300 |
| 52 Week Range | 0.0200 - 0.1450 |
| Volume | |
| Avg. Volume | 2,005,100 |
| Market Cap | 9.782M |
| Beta (5Y Monthly) | 2.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Medivolve Announces Results of Annual and Special Shareholder Meeting
TORONTO, June 16, 2022 (GLOBE NEWSWIRE) -- Medivolve, Inc. (“Medivolve” or the “Company”) (NEO: MEDV; OTC: COPRF; FRA:4NC), reports, in accordance with the policies of the NEO Exchange, that the nominees listed in the Management Information Circular dated May 16, 2022 for the 2022 Annual and Special Meeting of Shareholders of the Company (the “Meeting”) were elected as directors of the Company. 21.82% of all of the issued and outstanding shares of the Company were represented at the Meeting. Det
- GlobeNewswire
Medivolve Announces Q1 2022 Financial Results
Cash on hand was $8,327,812 as at March 31, 2022, up 7,309% compared to $112,397 as at December 31, 2021.Cash provided by operating activities was $8,211,415 in the three months ending March 31, 2022, compared to cash used by operating activities of $4,382,478 in the prior three months ending March 31, 2021.Revenue was $16,693,947 in the three months ending March 31, 2022, up 48%, compared to $11,248,001 over the prior three months ending March 31, 2021.Gross profit was $6,409,277 in the three m
- GlobeNewswire
Medivolve Announces Launch of Normal Course Issuer Bid
TORONTO, May 03, 2022 (GLOBE NEWSWIRE) -- Medivolve, Inc. (“Medivolve” or the “Company”) (NEO: MEDV; OTC: COPRF; FRA: 4NC) is pleased to announce its intention to commence a Normal Course Issuer Bid (“NCIB”) to buy back common shares of the Company (the “Common Shares”) through the facilities of NEO Exchange Inc. (the “Exchange”) and/or other Canadian alternative trading platforms. The actual number of Common Shares that may be purchased under the NCIB and the exact timing of such purchases will
